Articles Tagged With:
-
Higher Mortality Rates Among ICU Patients with Alzheimer’s Disease
Consider early and timely palliative care services instead of the ICU. Early exposure to palliative care may improve both survivability and quality of life, and may lower the risk of hospital-acquired infections.
-
Clinicians Need Proactive Approach to Ensure Ethical Artificial Intelligence Use
Rather than reacting to associated risks, clinicians implementing AI algorithms should ensure policies and safeguards are in place and routinely assess them. They also can be advocates for such protections through interactions with industries and organizations, as well as mentorship of trainees.
-
Literature Review Reveals Gaps in Research on Assisted Reproductive Technologies
Ethicists should consider the potential for discrimination and inequality in access to assisted reproductive technologies, and help make these solutions available to all who need them, regardless of their socioeconomic status, race, ethnicity, or other factors.
-
To Pay or Not to Pay: Researchers Grapple with Implications of Reimbursing Study Participants
Pushback on paying participants comes from both researchers and IRBs. From the researcher’s perspective, concerns revolve around budgetary limitations and how much they can afford to pay. IRBs generally are more concerned about payment amounts causing undue influence on participation.
-
Patients Say Researchers Are Ethically Obligated to Return Study Data
Returning patient-reported outcome data to study participants is a growing priority for researchers. it is important to do it in a way that is comprehensible, actionable, and aligned with participants’ preferences.
-
Growing Concerns About Health Data Use
A group recently outlined ethical, legal, and societal standards for data collection, use, and reuse to which researchers, technology companies, and others can be held accountable. The statement assures people the stewardship of their data is taken seriously, and that the company is committed to using it ethically.
-
Does Current IRB System Ensure Ethical Research?
A consensus is needed for how to measure IRB quality or effectiveness, and more inspections are needed to ensure instances of IRB noncompliance are identified, according to the authors of a recent report.
-
An RNA Shot for Hypertension?
One dose of a new RNA-based drug administered by subcutaneous injection, which blocks hepatic angiotensinogen production, resulted in sustained reductions in blood pressure in patients with hypertension for up to 24 weeks without any serious adverse effects.
-
Is the Combination of a GLP-1 Agonist and a SGLT2 Inhibitor Safe?
Adding a GLP-1 RA in a subgroup of type 2 diabetes patients on baseline SGLT2 inhibitor therapy revealed GLP-1 RA reduces major adverse cardiovascular event rates, regardless of baseline SGLT2 use.
-
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.